ecancermedicalscience

Submit article

https://doi.org/10.3332/ecancer.2008.121

Abstract | Full Article |

Short Communication

Azacitidine prolongs overall survival and reduces infections and hospitalisations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

10 Dec 2008

P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, G Sanz, AF List, SD Gore, JF Seymour, J Backstrom, L Zimmerman, D McKenzie, CL Beach, LB Silverman

Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (¡Ý20¨C30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival <1 year) and the poor response to chemotherapy in these pts, this sub-group analysis evaluated the effects of AZA versus conventional care regimens (CCR) on OS and on response rates in pts with WHO AML.

Article metrics: 2411 views

464

1947

2246-intended-and-completed-treatment-pathways-in-non-metastatic-oesophageal-cancer-treated-with-chemoradiotherapy-real-world-survival-and-swallowing-outcomes

Research: Intended and completed treatment pathways in non-metastatic oesophageal cancer treated with chemoradiotherapy: real-world survival and swallowing outcomes

Nikhil Bathija, Rohit Mahajan, Anil Kumar Goel, Siva Ranjani, Mounika Sirimalla, Gourav Kaushal, Sapna Marcus, Shilpa Jain, Madhur Verma, Deep Shikha, Korukonda Vinod Kumar, Jyoti Sharma

10 Nov 2026

https://doi.org/10.3332/ecancer.2026.2246

Abstract | Full Article | PDF

2244-validation-of-the-spanish-version-of-the-shame-and-sigma-scale-for-head-and-neck-cancer-survivors

Research: Validation of the Spanish version of the shame and sigma scale for head and neck cancer survivors

Loreto Fernández-González, Rodrigo Lagos, Piero Bettoli, Loreto Moreira, Jaime Sapag, David Kissane

3 Nov 2026

https://doi.org/10.3332/ecancer.2026.2244

Abstract | Full Article | PDF

2238-retrospective-analysis-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-treated-in-argentina-2018-2025-results-from-the-guia-2-study-in-real-world-clinical-practice

Research: Retrospective analysis of patients with locally advanced or metastatic urothelial carcinoma treated in Argentina (2018–2025): results from the GUIA 2 study in real-world clinical practice

Pablo Companys, Tomas Soule, Mariano Aymar, María Natalia Gandur Quiroga, Rosalía Hinojosa Altamirano, Marcelo Fogtman, Augusto Ferreyra Camacho, Rodrigo Sánchez, Gonzalo Taetti, Gabriela Gatica, Natalia Soto, María Elisa Arroyo, Nicolas Mainardi, Carolina Passarella, Andrea Marchioni, Ignacio Jerez, María Pía Domínguez, Emiliano Menna, Harold Somerville, Ernesto Korbenfeld, Florencia Sarru, Karina Peters, Iván Macharashvili, Federico Losco, Laura Pelagatti Santoni, Mauricio Fernández Lazaro, José Zarba, Mabel Gill, Juan Pablo Sade, Federico Cayol

21 Oct 2026

https://doi.org/10.3332/ecancer.2026.2238

Abstract | Full Article | PDF

2230-epstein-barr-virus-in-paediatric-sporadic-burkitt-lymphoma-real-world-experience-from-a-peruvian-national-referral-centre

Research: Epstein–Barr virus in paediatric sporadic Burkitt lymphoma: real-world experience from a Peruvian national referral centre

Sandro Casavilca-Zambrano, Juan Contreras-Mancilla, Camille Laurent, Jaqueline Montoya, Rosdali Diaz-Coronado, Jorge Honles, Ruddy Liendo-Picoaga, Jenny Bonifacio-Mundaca, Jhoysi Casas-Goñas, Juan Pablo Cerapio, Carlos Barrionuevo, Tatiana Vidaurre, Stéphane Bertani

8 Oct 2026

https://doi.org/10.3332/ecancer.2026.2230

Abstract | Full Article | PDF